Related Experiment Video
Updated: Jun 5, 2026
09:09
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
Azaindoles as potent CRTH2 receptor antagonists
Daniel Simard1, Yves Leblanc, Carl Berthelette
1Merck Frosst Centre for Therapeutic Research, 16711 Trans Canada Highway, Kirkland, Québec, Canada H9H 3L1. daniel.simard@merck.com
Bioorganic & Medicinal Chemistry Letters
|December 28, 2010
Summary
Researchers developed novel 7-azaindole analogs as potent and selective chemoattractant receptor-homologous 2 (CRTH2) antagonists. These compounds show promising potential for therapeutic applications by blocking CRTH2 activity.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- The chemoattractant receptor-homologous 2 (CRTH2) receptor plays a key role in inflammatory diseases.
- Development of selective CRTH2 antagonists is a therapeutic goal for conditions like asthma and allergic rhinitis.
- Existing CRTH2 antagonists have limitations, necessitating novel chemical scaffolds.
Purpose of the Study:
- To report a new class of 7-azaindole analogs as potent and selective CRTH2 antagonists.
- To detail the structure-activity relationship (SAR) for optimizing the azaindole scaffold.
- To characterize the pharmacokinetic properties and off-target activities of lead compounds.
Main Methods:
- Synthesis of diverse 7-azaindole analogs.
- In vitro evaluation of CRTH2 antagonist potency and selectivity.
- Structure-activity relationship (SAR) analysis to identify key structural features.
- In vivo pharmacokinetic (PK) studies.
- Off-target screening assays.
Main Results:
- Identification of a novel series of 7-azaindole analogs with high potency and selectivity for CRTH2.
- Optimization of the azaindole regioisomer led to significantly improved antagonist activity.
- Lead compounds exhibited favorable pharmacokinetic profiles.
- Demonstrated good selectivity with minimal activity against a panel of off-target receptors.
Conclusions:
- 7-azaindole analogs represent a promising new chemical class for CRTH2 antagonist development.
- The identified compounds possess drug-like properties suitable for further preclinical investigation.
- This work provides a foundation for developing novel therapeutics targeting CRTH2-mediated inflammatory conditions.
Related Concept Videos
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...